ANI Pharmaceuticals (NASDAQ:ANIP) Hits New 52-Week Low – Should You Sell?

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) reached a new 52-week low during trading on Wednesday . The stock traded as low as $69.96 and last traded at $70.4450, with a volume of 9889 shares traded. The stock had previously closed at $70.23.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on ANIP. Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Guggenheim cut their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research report on Monday, August 10th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Canaccord Genuity Group dropped their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $105.57.

ANI Pharmaceuticals Stock Up 0.3%

The company’s fifty day simple moving average is $78.12 and its 200-day simple moving average is $78.34. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a market capitalization of $1.62 billion, a PE ratio of 15.12 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business’s revenue for the quarter was up 25.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Insiders Place Their Bets

In other news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the transaction, the vice president owned 74,424 shares in the company, valued at $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $74.30, for a total transaction of $401,220.00. Following the completion of the sale, the chief executive officer owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,925 shares of company stock worth $1,728,385 in the last three months. Insiders own 8.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. KBC Group NV purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth $28,000. Advisors Asset Management Inc. acquired a new position in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. increased its position in shares of ANI Pharmaceuticals by 70.3% in the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after acquiring an additional 249 shares during the period. Kemnay Advisory Services Inc. purchased a new position in ANI Pharmaceuticals in the 4th quarter worth $48,000. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals in the 2nd quarter worth $50,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.